Article
Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.
International journal of cancer - 15 Nov 2009
Balmanno Kathryn, Chell Simon D, Gillings Annette S, Hayat Shaista, Cook Simon J
Abstract excerpt
Mutations in KRAS or BRAF frequently manifest in constitutive activation of the MEK1/2-ERK1/2 signalling pathway. The MEK1/2-selective inhibitor, AZD6244 (ARRY-142886), blocks ERK1/2 activation and is currently undergoing clinical evaluation. Tumour cells can vary markedly in their response to MAPK or ERK kinase (MEK) inhibitors, and the presence of a BRAF mutation is thought to predict sensitivity, with the RAS...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.